Tempus AI (TEM)
Nasdaq Market Open
Tempus AI, Inc. is a healthcare technology company focused on bringing artificial intelligence and large-scale data infrastructure into clinical care, drug development, and diagnostics. Its core offering is the Tempus Platform, which is designed to organize fragmented medical information and make it more useful for physicians, researchers, life sciences companies, and health systems.
The company works with clinical, molecular, imaging, and other real-world healthcare data, with a particular emphasis on precision medicine. By combining laboratory services, data analytics, and software tools, Tempus aims to help clinicians better understand a patient’s disease and support more individualized treatment decisions. Its intelligent diagnostics business includes genomic testing and related products that use AI, including generative AI techniques, to interpret complex datasets and improve the relevance of test results.
Tempus is best known for its role in oncology, where molecular profiling can guide therapy selection and clinical trial matching, but its platform is built to support broader use cases across disease areas. The company also serves biopharmaceutical partners by providing data-driven insights that can inform research, patient identification, and drug development strategies.
For investors, Tempus represents exposure to the intersection of healthcare data, diagnostics, and applied AI. Its business depends on the continued adoption of precision medicine, demand for advanced testing, and the ability to turn healthcare information into actionable insights while operating in a regulated medical environment.
Last updated
- Market Cap
- 8.53B
- P/E
- —
- P/FCF
- —
- P/S
- 6.25
- Enterprise Value
- 9.26B
- Sector
- —
- Industry
- —
- Address
- 600 WEST CHICAGO AVENUE, CHICAGO, IL, 60654
Artificial Intelligence Clinical Trial Protocol Feasibility Tool Research Report 2026: $2.75+ Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2035F
Real-World Data on Healthcare Technology Adoption: Company Insights and Government Trends with Key Statistics (e.g., 71% U.S. Hospitals Adoption, $3B Company Valuations)
Esoteric Testing Research Report 2026 - Global $41.5+ Bn Market Trends, Opportunities, and Forecasts to 2031
4 Hyper-Growth Stocks Ready to Dazzle This Earnings Season
Q4 Earnings Preview: Wall Street’s Make-or-Break Moment as Reporting Season Looms
Physical AI Market Size to Expand at 31.26% CAGR, to Capture USD 61.19 Billion 2034
Tempus AI: Volatility Equates to Opportunity in AI Leader
Tempus AI Hits $100—Are Shares Due for a Pullback?
3 Healthcare Stocks Using AI to Drive Growth
TEMPUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Tempus AI, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Tempus AI: Strong Q2 Fuels Growth Story—More Upside Ahead?
DEADLINE ALERT for RCKT, DDD, TEM, RDDT: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
Tempus AI: Q2 Earnings Mark a Turning Point in AI-Powered Healthcare Strategy
AUGUST 11 DEADLINE: Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law
TEMPUS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Tempus AI, Inc. and Encourages Investors to Contact the Firm
Deadline Alert: Tempus AI, Inc. (TEM) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
TEMPUS AI SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Tempus AI, Inc. - TEM
TEM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vestis and Tempus and Encourages Investors to Contact the Firm
DEADLINE ALERT for RCKT, DDD, TEM, RDDT: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 8.53B
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 9.26B
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 20.49
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 6.25
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -65.95
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 6.79
- EPS
- -1.69
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -212.92M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -72.74%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -14.19%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 3
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 3.31
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 3.15
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 1.64
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 6.24M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 47.51
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 348.12M | 367.21M | 334.21M | 314.64M | 255.74M |
| Gross profit | 222.04M | 237.71M | 209.94M | 195.04M | 155.2M |
| Operating income | -84.71M | -61.41M | -61M | -61.77M | -68.69M |
| EBITDA | -58.54M | -34.51M | 14.42M | -61.77M | -48.34M |
| Net income | -125.92M | -54.17M | -79.98M | -42.84M | -68.04M |
| Basic EPS | -0.7 | -0.31 | -0.46 | -0.25 | -0.4 |
| Diluted EPS | -0.71 | -0.31 | -0.46 | -0.25 | -0.4 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 2.14B | 2.27B | 2.28B | 1.63B | 1.54B |
| Total liabilities | 1.72B | 1.78B | 1.77B | 1.32B | 1.22B |
| Total equity | 416.41M | 491.33M | 507.82M | 309.56M | 326.19M |
| Cash & equivalents | 521.17M | 604.79M | 655.92M | 186.31M | 151.6M |
| Current assets | 1.05B | 1.17B | 1.15B | 644.2M | 573.97M |
| Current liabilities | 317.96M | 372.39M | 350.03M | 418.16M | 336.47M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -73.28M | -36.79M | -119.84M | 44.16M | -105.62M |
| Investing cash flow | -10.07M | -10.72M | -2.31M | -9.51M | -375.82M |
| Financing cash flow | -271K | -3.61M | 594.69M | 0 | 293.04M |
| Change in cash | -83.59M | -51.1M | 472.5M | 34.73M | -188.51M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 4 — Tempus AI, Inc. | View Filing | |
| edgar index | 144 — Tempus AI, Inc. | View Filing | |
| form 4 | Form 4 — LEFKOFSKY ERIC P | View Filing | |
| form 4 | Form 4 — LEFKOFSKY ERIC P | View Filing | |
| form 4 | Form 4 — LEFKOFSKY ERIC P | View Filing | |
| form 4 | Form 4 — LEFKOFSKY ERIC P | View Filing | |
| form 4 | Form 4 — LEFKOFSKY ERIC P | View Filing | |
| form 4 | Form 4 — LEFKOFSKY ERIC P | View Filing | |
| form 4 | Form 4 — LEFKOFSKY ERIC P | View Filing | |
| form 4 | Form 4 — LEFKOFSKY ERIC P | View Filing | |
| form 4 | Form 4 — LEFKOFSKY ERIC P | View Filing | |
| form 4 | Form 4 — LEFKOFSKY ERIC P | View Filing | |
| edgar index | 4 — Tempus AI, Inc. | View Filing | |
| edgar index | 4 — Tempus AI, Inc. | View Filing | |
| edgar index | 4 — Tempus AI, Inc. | View Filing | |
| edgar index | 4 — Tempus AI, Inc. | View Filing | |
| edgar index | 4 — Tempus AI, Inc. | View Filing | |
| edgar index | 4 — Tempus AI, Inc. | View Filing | |
| edgar index | 4 — Tempus AI, Inc. | View Filing | |
| edgar index | 4 — Tempus AI, Inc. | View Filing | |
| edgar index | 8-K — Tempus AI, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Tempus AI, Inc. | View Filing | |
| edgar index | 4 — Tempus AI, Inc. | View Filing | |
| edgar index | 4 — Tempus AI, Inc. | View Filing | |
| edgar index | 4 — Tempus AI, Inc. | View Filing | |
| edgar index | 4 — Tempus AI, Inc. | View Filing | |
| edgar index | 4 — Tempus AI, Inc. | View Filing | |
| form 4 | Form 4 — BARRIS PETER J | View Filing | |
| form 4 | Form 4 — Belcher Eric D | View Filing | |
| form 4 | Form 4 — Belcher Eric D | View Filing | |
| form 4 | Form 4 — Gottlieb Scott | View Filing | |
| form 4 | Form 4 — Epstein David R | View Filing | |
| form 4 | Form 4 — Leonsis Theodore | View Filing | |
| form 4 | Form 4 — Leonsis Theodore | View Filing | |
| form 4 | Form 4 — Doudna Jennifer A | View Filing | |
| form 4 | Form 4 — West Nadja | View Filing | |
| form 4 | Form 4 — Frederick Wayne A.I. | View Filing | |
| edgar index | 144 — Tempus AI, Inc. | View Filing | |
| edgar index | 144 — Tempus AI, Inc. | View Filing | |
| edgar index | 144 — Tempus AI, Inc. | View Filing | |
| edgar index | 144 — Tempus AI, Inc. | View Filing | |
| edgar index | 144 — Tempus AI, Inc. | View Filing | |
| edgar index | 144 — Tempus AI, Inc. | View Filing | |
| edgar index | 144 — Tempus AI, Inc. | View Filing | |
| form 4 | Form 4 — LEFKOFSKY ERIC P | View Filing | |
| form 4 | Form 4 — LEFKOFSKY ERIC P | View Filing | |
| form 4 | Form 4 — LEFKOFSKY ERIC P | View Filing | |
| form 4 | Form 4 — LEFKOFSKY ERIC P | View Filing | |
| form 4 | Form 4 — LEFKOFSKY ERIC P | View Filing | |
| form 4 | Form 4 — LEFKOFSKY ERIC P | View Filing | |
| form 4 | Form 4 — LEFKOFSKY ERIC P | View Filing | |
| form 4 | Form 4 — LEFKOFSKY ERIC P | View Filing | |
| form 4 | Form 4 — Bartolucci Ryan M | View Filing | |
| form 4 | Form 4 — Polovin Andrew | View Filing | |
| form 4 | Form 4 — Fukushima Ryan | View Filing | |
| form 4 | Form 4 — Fukushima Ryan | View Filing | |
| form 4 | Form 4 — Rogers James William | View Filing | |
| form 4 | Form 4 — Schoenherr Thomas Edward | View Filing | |
| edgar index | 4 — Tempus AI, Inc. | View Filing | |
| form 4 | Form 4 — Fukushima Ryan | View Filing | |
| form 4 | Form 4 — Fukushima Ryan | View Filing | |
| edgar index | 8-K — Tempus AI, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — Tempus AI, Inc. | View Filing | |
| edgar index | 4 — Tempus AI, Inc. | View Filing | |
| edgar index | 4 — Tempus AI, Inc. | View Filing | |
| edgar index | 4 — Tempus AI, Inc. | View Filing | |
| edgar index | 4 — Tempus AI, Inc. | View Filing | |
| edgar index | 4 — Tempus AI, Inc. | View Filing | |
| edgar index | 8-K — Tempus AI, Inc. | View Filing | |
| edgar index | 10-Q — Tempus AI, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Bartolucci Ryan M | View Filing | |
| form 4 | Form 4 — Polovin Andrew | View Filing |